Celldex Therapeutics (NASDAQ:CLDX) Share Price Passes Above 200 Day Moving Average - Should You Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $21.24 and traded as high as $22.37. Celldex Therapeutics shares last traded at $21.98, with a volume of 978,039 shares traded.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Celldex Therapeutics in a research report on Friday, June 13th. Morgan Stanley reduced their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. The Goldman Sachs Group reduced their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. Finally, UBS Group reduced their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.11.

Celldex Therapeutics Stock Down 4.6%

The stock has a 50 day moving average price of $20.36 and a 200 day moving average price of $21.13. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -7.77 and a beta of 1.13.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 2,366.07% and a negative return on equity of 23.46%. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC boosted its holdings in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Celldex Therapeutics by 6,665.9% in the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after acquiring an additional 2,933 shares during the last quarter. Headlands Technologies LLC bought a new stake in Celldex Therapeutics in the fourth quarter valued at approximately $81,000. AlphaQuest LLC boosted its holdings in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Celldex Therapeutics in the fourth quarter valued at approximately $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.